During this virtual event, Esther McNamara, ILC's Senior Health Policy Lead, presents the Trial and error report’s findings and recommendations. A panel of five experts respond to the report and discuss how improved age diversity will benefit patients of all ages.

1. Launching Trial and error:
Supporting age diversity in
clinical trials
Join the conversation: @ilcuk
#TrialandError

2. @ilcuk
#TrialandError
Launching Trial and error: Supporting age
diversity in clinical trials
Dave Valacer MD
Regor Pharmaceuticals
regor.com
Esther McNamara
ILC-UK
@ilcuk
Pol Vandenbroucke
Global Longevity Council
ILC Trustee
@ilcuk
Mike Keens
Thompson Street Capital
Partners
@keensmike
Rosemary Lakeru
Acorn IQ
acorniq.co
Chair: Emma Thorp
RBW Consulting
@RBWConsulting
Professor Miles Witham
Newcastle University
@OlderTrialsProf
@UniofNewcastle

3. Emma Thorp
Chief Commercial Officer
RBW Consulting
Join the conversation: @ilcuk
#TrialandError

4. Pol Vandenbroucke
Chair, Global Longevity Council
ILC Trustee
Join the conversation: @ilcuk
#TrialandError

5. Discussion panel
Mike Keens, Operating Executive, Thompson Street Capital Partners
Rosemary Lakeru, Founder & CEO, Acorn IQ
Dave Valacer MD, Chief Medical Officer, Regor Pharmaceuticals
Professor Miles Witham, Professor of Trials for Older People, Newcastle
University

6. Esther McNamara
Project Lead & Senior Health Policy Lead
ILC-UK
esthermcnamara@ilcuk.org.uk
Join the conversation: @ilcuk
#TrialandError

7. We found that the key barriers to age parity in clinical trial cohorts are:
• Cost
• ‘Clean’ data
• Arbitrary exclusions
• Practical considerations
Some great strides are being taken towards age diversity, but progress is
inconsistent with the needs of ageing populations.
Key findings

8. Our recommendations
Co-produce new guidelines to replace
ICH-E7
Increase incentives for age-diverse
cohorts
Prioritise gathering age-related data in
all trials
Introduce ‘gold standard’ for inclusive
trials
Expand existing D&I initiatives to
include age
Appoint diversity champions in all trials
Invest in technological advances to
support participation
Ringfence funding for consistent patient
and public involvement

9. Recommendation #1
New guidelines to replace ICH-E7
These would be co-produced by regulators, pharmaceutical
companies, academic researchers, and other stakeholders.
Join the conversation: @ilcuk
#TrialandError

10. Recommendation #2
Regulators should incentivise investment in
age diverse trial cohorts.
Join the conversation: @ilcuk
#TrialandError

11. Recommendation #3
Researchers and companies should prioritise gathering age-
specific data across all trials.
Join the conversation: @ilcuk
#TrialandError

12. Recommendation #4
Development of consistent Patient and Public Involvement (PPI)
infrastructure across the sector.
Join the conversation: @ilcuk
#TrialandError

13. Q&A
Please submit your questions in the Q&A
section

14. Closing remarks

15. Upcoming events
Healthy ageing:
Priorities for the G20
in India
Webinar
Tuesday 25 April
G7 high-level side
events in Japan:
Healthy ageing and
prevention
10 May - Niigata
18 May - Hiroshima
Global launch of the
Healthy Ageing and
Prevention Index - 76th
World Health Assembly
Geneva, Switzerland
Tuesday 23 May

16. Thank you!
ilcuk.org.uk
rbwconsulting.com